We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use beyond acute pain management.

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. Whatever happens, though ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) have been assigned a consensus recommendation ...